Abstract
The platelet is central to the pathophysiology of acute coronary syndromes (ACS) via its direct participation in the formation of the thrombotic occlusion and its participation in the coagulation cascade that results in the formation of thrombin. Antiplatelet therapy is a cornerstone of therapy in the setting of ACS. Unfortunately, many patients who receive intensive antiplatelet therapy remain at high risk for recurrent events. Current efforts to reduce this “residual risk” include lifestyle modifications, cardiac rehabilitation, and intensive therapy for dyslipidemia. Also being investigated are methods of individualizing and intensifying antiplatelet therapy. Novel compounds that promise to reduce recurrent ischemic events without an increase in bleeding events are being evaluated in clinical trials. This review summarizes ongoing efforts to improve the effectiveness of antiplatelet therapy among patients with ACS.
Keywords: Antiplatelet therapy, acute coronary syndromes, coronary artery disease, residual risk, ACS, treatment, P2Y12 receptor antagonists, thrombin receptor antagonism, Vorapaxar, PAR1
Current Drug Targets
Title: Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 Inhibition and Thrombin Receptor Antagonists
Volume: 12 Issue: 12
Author(s): Alison L. Bailey and Charles L. Campbell
Affiliation:
Keywords: Antiplatelet therapy, acute coronary syndromes, coronary artery disease, residual risk, ACS, treatment, P2Y12 receptor antagonists, thrombin receptor antagonism, Vorapaxar, PAR1
Abstract: The platelet is central to the pathophysiology of acute coronary syndromes (ACS) via its direct participation in the formation of the thrombotic occlusion and its participation in the coagulation cascade that results in the formation of thrombin. Antiplatelet therapy is a cornerstone of therapy in the setting of ACS. Unfortunately, many patients who receive intensive antiplatelet therapy remain at high risk for recurrent events. Current efforts to reduce this “residual risk” include lifestyle modifications, cardiac rehabilitation, and intensive therapy for dyslipidemia. Also being investigated are methods of individualizing and intensifying antiplatelet therapy. Novel compounds that promise to reduce recurrent ischemic events without an increase in bleeding events are being evaluated in clinical trials. This review summarizes ongoing efforts to improve the effectiveness of antiplatelet therapy among patients with ACS.
Export Options
About this article
Cite this article as:
L. Bailey Alison and L. Campbell Charles, Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 Inhibition and Thrombin Receptor Antagonists, Current Drug Targets 2011; 12 (12) . https://dx.doi.org/10.2174/138945011797635830
DOI https://dx.doi.org/10.2174/138945011797635830 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Strategy on Antimicrobial-resistance: Inhibitors of DNA Replication Enzymes
Current Medicinal Chemistry Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Potential Approaches to Enhance the Effects of Estrogen on Senescent Blood Vessels and Postmenopausal Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Anticancer Drug Discovery using Chemical Genomics
Current Medicinal Chemistry Genesis of Dihydropyrimidinone Calcium Channel Blockers: Recent Progress in Structure-Activity Relationships and Other Effects
Mini-Reviews in Medicinal Chemistry Expression and Role of the Calcium-Sensing Receptor in the Blood Vessel Wall
Current Pharmaceutical Biotechnology Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Molecular Determinants of the Cardiometabolic Phenotype
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Atherosclerotic Therapy Based on Botanicals
Recent Patents on Cardiovascular Drug Discovery Biomarkers of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), A Review of Published Patents and Patent Applications
Recent Patents on Biomarkers Microcirculatory Endothelial Dysfunction During Endotoxemia - Insights into Pathophysiology, Pathologic Mechanisms and Clinical Relevance
Current Vascular Pharmacology Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews Bortezomib – First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Synthesis and Antiproliferative Activity of New Polyoxo 2-Benzyl-2,3- dihydrobenzofurans and Their Related Compounds
Letters in Drug Design & Discovery Does Data Shape Moral Decision? Or Do Values Shape the Data?
Current Pediatric Reviews Antithrombotic Therapy
Current Molecular Medicine Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Current Vascular Pharmacology Amiodarone Hepatotoxicity
Current Vascular Pharmacology Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events
Current Drug Targets Investigating Physical, Psychological and Social Well-being of Older Persons in Jordan
Current Aging Science